SEC Comment Letter 0000000000-23-010974 to NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (NBY)

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: Oct. 5, 2023 · CIK: 0001389545 · Accession: 0000000000-23-010974

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-33678

Date

October 5, 2023

Author

Not clearly detected

Form

UPLOAD

Company

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)

Letter

United States securities and exchange commission logo October 5, 2023 Justin Hall Chief Executive Officer NovaBay Pharmaceuticals, Inc. 2000 Powell Street, Suite 1150 Emeryville, California 94608 Re:NovaBay Pharmaceuticals, Inc. Definitive Proxy Statement on Schedule 14A Filed May 18, 2023 File No. 001-33678 Dear Justin Hall: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Disclosure Review Program

Show Raw Text

United States securities and exchange commission logo
October 5, 2023
Justin Hall
Chief Executive Officer
NovaBay Pharmaceuticals, Inc.
2000 Powell Street, Suite 1150
Emeryville, California 94608
Re:NovaBay Pharmaceuticals, Inc.
Definitive Proxy Statement on Schedule 14A
Filed May 18, 2023
File No. 001-33678
Dear Justin Hall:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Disclosure Review Program

SecProbe.io